Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Express Scripts
Colorcon
Harvard Business School
Merck

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,188,732

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,188,732
Title:Methods and compositions for inactivating enveloped viruses
Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
Inventor(s): Conley; Lynn Edward (Raleigh, NC), Tao; Yinying (Morrisville, NC)
Assignee: Biogen MA Inc. (Cambridge, MA)
Application Number:14/419,968
Patent Claims:1. A method of inactivating an enveloped virus in a recombinant protein preparation, the method comprising contacting a recombinant protein preparation that comprises a recombinant protein with N,N-dimethyldodecyclamine N-oxide (LDAO) in an amount sufficient to inactivate the enveloped virus, wherein the amount is at a concentration above critical micelle concentration of the LDAO and does not inhibit biological activity of the recombinant protein.

2. The method of claim 1, wherein the method further comprises culturing in cell culture media cells that express the recombinant protein.

3. The method of claim 1, wherein the method further comprises purifying the recombinant protein.

4. The method of claim 2, wherein the recombinant protein preparation is contacted with the LDAO detergent before, during, or after the culturing step.

5. The method of claim 3, wherein the recombinant protein preparation is contacted with the LDAO during the purifying step.

6. The method of claim 1, wherein the concentration above the critical micelle concentration is about 2 times to about 10 times the critical micelle concentration.

7. The method of claim 1, wherein greater than about 4 log inactivation of the enveloped virus is achieved within 1 hour of contacting the recombinant protein preparation with the LDAO.

8. The method of claim 1, wherein the recombinant protein is a tumor necrosis factor (TNF) inhibitor protein.

9. The method of claim 8, wherein the TNF inhibitor protein is etanercept.

10. The method of claim 1, wherein the enveloped virus is associated with a rodent cell line or a mammalian cell line.

11. The method of claim 10, wherein the enveloped virus is Xenotropic Murine Leukemia Virus.

12. The method of claim 10, wherein the enveloped virus is Suid Herpesvirus 1.

13. The method of claim 1, wherein the method does not comprise contacting the recombinant protein preparation with a solvent.

14. The method of claim 1, wherein the amount of LDAO is 0.01% to 0.2% weight/volume (w/v) of the recombinant protein preparation.

Details for Patent 10,188,732

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Sign up for a Free Trial 2032-08-06
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Sign up for a Free Trial 2032-08-06
Immunex Corporation ENBREL etanercept Injection 103795 2004-09-27 ⤷  Sign up for a Free Trial 2032-08-06
Immunex Corporation ENBREL etanercept Injection 103795 2007-02-01 ⤷  Sign up for a Free Trial 2032-08-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.